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Background: Over time, a patient-centered evaluation of health status has become more 
important for systemic sclerosis (SSc), both in research and clinical setting. Patient-reported 
outcomes (PROs) are being increasingly used to measure various domains of disease status 
relevant to patients and physicians. The EULAR Outcome Measures Library (OML) is a freely 
available website with structured access to a growing database of validated PROs [1], but 
currently there are no PROs available on SSc at the EULAR OML. 
Objectives: To provide a comprehensive review of validated SSc-specific PROs and to critically 
appraise their validity. 
Methods: A sensitive search was developed in Medline and Embase (08/2015) to identify all 
validation studies, cohort studies, reviews or metaanalyses in which the objective were the 
development or validation of PROs evaluating organ involvement, disease activity or damage in 
SSc. A reviewer screened title and abstracts, selected the studies, and collected data concerning 
validation using ad hoc forms based on the COSMIN checklist. 
Results: From 13,140 articles captured, 74 met the predefined criteria. After excluding an 
instrument for the unavailability of an English version, the selected studies provided information 
on 6 SSc-specific PROs: the Scleroderma Assessment Questionnaire (SAQ), the scleroderma 
functional score (FS), the Raynaud's condition score (RCS), the Mouth Handicap in SSc 
(MHISS), the University of California Los Angeles-Scleroderma Clinical Trial Consortium Gastro-
Intestinal tract (UCLA-SCTC-GIT 2.0), and the Skin Self-Assessment. The table summarizes the 
instruments and their measurement properties: 
 
Table 1 
SSc-
specific 
PROs 
Domains 
No. of 
items 
and 
range 
Measurement properties 
   
Reliability 
IC/TR/ME 
Validity 
Responsivene
ss 
Interpretability 
SAQ 
Functional 
status 
(vascular, 
respiratory, 
GIT and 
musculoskelet
al apparatus) 
Items: 
23Rang
e: 0–3 
ICC 0.79–
0.95 
Total score 
higher in 
pts with 
systemic 
involvement 
Vascular 
z=0.92–2.97; 
Respiratory 
z=1.34–2.52; 
GIT z=−3.14–
4.03; 
Musculoskeletal 
status z=0.68–
3.16 
– 
FS 
Functional 
ability (upper 
limbs & 
muscle 
weakness) 
Items: 
11Rang
e: 0–33 
Intra-
observkw 0.1
9–0.6inter-
observkw0.69
–0.94 
HAQ-DI 
r=0.90Skin 
score 
r=0.11 
FS correlates 
with HAQ-DI 
0.59, & Hand 
HAQ-DI 0.58 
– 
RCS 
Severity and 
impact of 
Raynaud's 
phenomenon 
Item: 
1Range 
0–10 
ICC 0.70 
Disease 
activity, Rp 
measures, 
digital 
ulcers, 
mood/tensi
on 67% 
variance 
ES 0.6SRM 
0.64 
MID 14–15 points 
(0–100 VAS)PASS 
34 points 
MHISS Disability Items: ICC 0.96 HAQ – – 
involving the 
mouth 
12Rang
e: 0–48 
r=0.33, 
CHFS 
r=0.37, 
mouth 
opening 
r=−0.34, 
MACTAR 
r=0.11, 
HADd 
r=0.26, 
HADa 
r=0.17 
UCLA 
SCTC GIT 
2.0 
GIT 
symptoms 
severity 
Items: 
34Rang
e: 0–3 
Cronbach's 
α>0.70, 
constipation 
(α=0.67)ICC 
0.71 
Total GIT 
score 
r=0.60; 
Upper GIT 
r=0.52; 
Lower GIT 
r=0.60 
rho 0.05–0.48 
MID/improvement: 
0.07–
0.36;MID/worseni
ng: 0.06 
−0.21;Floor: 
noneCeiling: 4% 
Skin self-
assessme
nt 
Skin 
thickening 
Items: 
17Rang
e: 0–51 
ICC 0.5–0.61 
Skin score 
r=0.435 
No changes 1 
yr follow-up 
– dcSScFloor 
<15%Ceiling 
<15%– lcSScFloor 
>15%Ceiling n.a. 
 
 
Conclusions: Six SSc-specific PROs have a minimum validation and will be included in the 
EULAR OML. In general, the level of validation attained could be improved. Further development 
in the area of disease-specific PROs in SSc is warranted. 
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